Rudolf de Boer


Rudolf de Boer (1972, Gouda, the Netherlands) is a Clinical Cardiologist and Professor of Translational Cardiology at the University Medical Center Groningen, the Netherlands.

Doctor de Boer’s clinical interests are cardiogenetics, cardio-oncology and end-stage heart failure including VAD therapy and transplant.   Professor de Boer has several research lines, and has authored over 400 articles. He received grants from the Netherlands Heart Foundation, the Dutch Organization for Scientific Research, and the European Research Council (ERC). He was appointed a Fellow of the European Society of Cardiology (ESC) in 2010, was Board Member of the Heart Failure Association (HFA) of the ESC from 2014-2020, and currently is Liaison Officer of the ESC Cardio-Oncology Council.  He has served as the president of the Heart Failure Working Group of the Dutch Society of Cardiology from 2014-2019, and is President-Elect of the Dutch Cardiac Society per April 2021.

Contact details

Current activities

The group of Rudolf de Boer works in translational cardiology, with a focus on heart failure, aiming to uncover novel pathways, proteins and biomarkers to better understand the pathophysiology. The projects span from experimental studies all the way to clinical studies. Currently, we focus on reverse Cardio-oncology, on diabetes and HFpEF and on genetic cardiomyopathies.

Current projects

European Research Council (ERC):
SECRETE-HF: It has been recognized that cancer may develop in response to cancer treatments. However, herein, we have showed for the first time that cancer is more prevalent in patients with heart failure and CV disease. This is an entirely new field with a large number of subprojects, from cell studies to animal studies, but also including patient cohorts.

Collaborators: Professor Alexander Lyon (Imperial College, London, UK), Professor Javid Moslehi (Nashville University, Tennessee, USA), and Professor Rienk Nieuwland (Amsterdam UMC).


Heart Foundation:
CVON-DOUBLE DOSE:  This project has recently been awarded, and focuses on environmental factors and stressors and onset of genetic cardiomyopathies. This is a large national collaboration with Amsterdam, Utrecht, Erasmus MC and Maastricht. Collaborators: Professor Jolanda van der Velden (Amsterdam UMC); Professor Folkert Asselbergs and Professor Peter van Tintelen (UMC Utrecht), Dr. Michelle Michels (Erasmus MC, Rotterdam), and Professor Silvia Evers and Stephane Heymans (Maastricht).

CVON SHE-PREDICTS-HF: Sex-specific predictors of new onset heart failure. We make use of large community dwelling cohorts, with a large number of cardiovascular biomarkers. Collaborators: Dr. Vannessa van Empel, Professor Stephane Heymans & Professor Blanche Schroen (Maastricht UMC).

CVON RED CVD: Early detection of heart failure, atrial fibrillation and coronary artery disease is difficult and suboptimal in primary care. This project includes a cluster randomized trial in primary care practices in an effort to optimize early recognition.  Collaborators: Professor Frans Rutten (Julius Center & UMC Utrecht), Professor Arno Hoes (UMC Utrecht).

PREDICT-2: Consortium working on sudden cardiac death. We will study mutations in phospholamban as a cause for sudden death. Collaborators: Professor Arthur Wilde (Amsterdam UMC), Professor Mark Vos (UMC Utrecht), Professor Paul Volders (Maastricht UMC).


Clinical trials:

My group has several clinical studies in its portfolio, usually in line with our other scientific projects. I have been Dutch National lead on the DAPA-HF trial, a landmark trial with the SGLT2 inhibitor in heart failure. I am member of the executive committee of DELIVER, that studies dapagliflozin in HFpEF. Furthermore, I have been studying biomarkers in heart failure, and am co-PI of the MONITOR HF study, a study that evaluates the pulmonary artery pressure monitor in severe heart failure.


LeDucq Foundation:

CURE-PLaN: In our part of the country, we have a high prevalence of cardiomyopathy due to a founder mutation in the phospholamban (PLN) gene. We have secured substantial funding to work on several aspects of the PLN gene. For more information, go to the CURE-PLaN website.

My projects


Predicting new-onset heart failure in women


Secreted factors in cardiac remodeling provoke tumorigenesis and end organ damage in heart failure


PHOspholamban RElated CArdiomyopathy STudy


Improving early detection of CVD

PLN cardiomyopathy

Investigating and treating phospholamban cardiomyopathy


Facilitate personalized therapies in patients with heart failure


Stem cell models to unravel the susceptibility and resilience to develop heart failure


MITOchondrial therapy to increase cardiac FORCE and enhance exercise performance


Personalised Medicine in Chronic Disease Management

My publications

Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients

Sophie L van Veldhuisen, Gijs van Woerden, Martin E W Hemels, Yves G C J America, Rudolf A de Boer, Michiel Rienstra, Dirk J van Veldhuisen, Eric J Hazebroek. Surg Obes Relat Dis 2021.

view on PubMed

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy

Tim R Eijgenraam, Bastiaan J Boukens, Cornelis J Boogerd, Marloes Schouten, Cees W A van de Kolk, Nienke M Stege, Wouter P Te Rijdt, Edgar T Hoorntje, Paul A van der Zwaag, Eva van Rooij, J Peter van Tintelen, Maarten P van den Berg, Peter van der Meer, Jolanda van der Velden, Herman H W Silljé, Rudolf A de Boer. Sci Rep. 2020

view on PubMed

Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers with Incident Heart Failure

Navin Suthahar, Emily S. Lau, Michael J. Blaha, Samantha M. Paniagua, Martin G. Larson, Bruce M. Psaty, Emelia J. Benjamin, Matthew A. Allison, Traci M. Bartz, James L. Januzzi Jr., Daniel Levy, Laura M.G. Meems, Stephan J.L. Bakker, Joao A.C. Lima, Mary Cushman, Douglas S. Lee, Thomas J. Wang, Christopher R. deFilippi, David M. Herrington, Matthew Nayor, Ramachandran S. Vasan, Julius M. Gardin, Jorge R. Kizer, Alain G. Bertoni, Norrina B. Allen, Ron T. Gansevoort, Sanjiv J. Shah, John S. Gottdiener, Jennifer E. Ho and Rudolf A. de Boer

view online: Journal of the American College of Cardiology

Sex-related differences in contemporary biomarkers for heart failure: a review.

Suthahar N, Meems LMG, Ho JE, de Boer RA. Eur J Heart Fail. 2020.

view on PubMed

High-sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences between Women and Men.

Suthahar N, Meems LMG, van Veldhuisen DJ, Walter JE, Gansevoort RT, Heymans S, Schroen B, van der Harst P, Kootstra-Ros JE, van Empel V, Mueller C, Bakker SJL, de Boer RA. Mayo Clin Proc. 2020.

Available on PubMed